API PHARMA
Annual accounts 2025
micro format, filed on 06-07-2026, 25 days before the deadlineTurnover and EBIT margin are not published. The micro format does not require them. The turnover shown is an estimate from the gross margin.
Turnover ≈ €250,000. Estimated: probably between €140,000 and €340,000.
Balance sheet
balance sheet total €116,460 on 31-12-2025in euro
in euro
Position in the sector
59.7%
Higher than 72% of 25,237 companies in 2025.
2.40
Higher than 70% of 24,245 companies in 2025.
28.5%
Higher than 91% of 24,434 companies in 2025.
Net result: top quarter · Equity: middle half · Balance sheet total: middle half · Working capital: middle half
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Balance sheet: assets | ||||
20/58 |
116,460 | 81,294 | 23,346 | |
21/28 |
15,037 | 23,689 | - | |
22/27 |
15,037 | 23,689 | - | |
24 |
15,037 | 23,689 | - | |
29/58 |
101,423 | 57,606 | 23,346 | |
40/41 |
10,992 | 10,945 | 8,083 | |
40 |
10,992 | 10,945 | 8,083 | |
54/58 |
90,141 | 46,660 | 14,879 | |
490/1 |
290 | - | 384 | |
| Balance sheet: equity and liabilities | ||||
10/49 |
116,460 | 81,294 | 23,346 | |
10/15 |
69,569 | 37,239 | 3,122 | |
10/11 |
2,000 | 2,000 | 2,000 | |
14 |
67,569 | 35,239 | 1,122 | |
17/49 |
46,890 | 44,056 | 20,224 | |
17 |
4,648 | 11,397 | - | |
170/4 |
4,648 | 11,397 | - | |
42/48 |
42,243 | 32,658 | 20,224 | |
42 |
6,750 | 6,493 | - | |
44 |
493 | 1,761 | 1,415 | |
440/4 |
493 | 1,761 | 1,415 | |
45 |
27,605 | 17,551 | 8,226 | |
450/3 |
26,005 | 15,951 | 5,476 | |
454/9 |
1,600 | 1,600 | 2,750 | |
47/48 |
7,395 | 6,852 | 10,583 | |
| Income statement | ||||
9900 |
52,678 | 50,122 | 3,020 | |
630 |
8,652 | 2,269 | - | |
640/8 |
365 | 2,726 | 321 | |
9901 |
43,660 | 45,127 | 2,699 | |
65/66B |
709 | 278 | 9 | |
65 |
709 | 278 | 9 | |
9903 |
42,951 | 44,849 | 2,690 | |
67/77 |
9,788 | 9,873 | 735 | |
9904 |
33,164 | 34,976 | 1,955 | |
9905 |
33,164 | 34,976 | 1,955 | |
| Appropriation of the result | ||||
9906 |
68,402 | 36,098 | 1,955 | |
14P |
35,239 | 1,122 | - | |
694/7 |
833 | 859 | 833 | |
694 |
833 | 859 | 833 | |
| Document | ||||
The notes to these accounts have 5 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the accounts filed with the NBB.
Source: Annual accounts 2025 at the NBB, filed on 06-07-2026.
Filings
each dot is a set of accounts, on the day it reached the National BankKey figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| 52,312 | 47,396 | - | ||
| 41,815 | 37,245 | - | ||
| 0 | 25,958 | - | ||
| 43,480 | 31,782 | - | ||
| 59,180 | 24,947 | 3,122 | ||
| 59.7% | 45.8% | 13.4% | ||
| 2.40 | 1.76 | 1.15 | ||
| 0.67 | 1.18 | 6.48 | ||
| 47.7% | 93.9% | 62.6% | ||
| 28.5% | 43.0% | 8.4% | ||
| 73.80 | over 100 | - |
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Investments
fixed assets acquired| Item | 2025 | 2024 | 2023 |
|---|---|---|---|
| Tangible fixed assets | - | €25,958 | - |
| €8,652 | €2,269 | - |
Source: notes to the 2023 to 2025 annual accounts (statement of fixed assets)
Insights on API PHARMA
The operating result for 2025 is 3% lower than in 2024.
Debt's share of the balance-sheet total falls from 54.2% to 40.3%. Equity and debt are higher.